Cristal Therapeutics

Cristal Therapeutics is a private, platform-focused biotech company founded in 2011 and headquartered in Maastricht, Netherlands. Its core asset is the CliCr® platform, a copper-free click chemistry technology designed for efficient and stable bioconjugation, primarily targeting the oncology and drug delivery sectors. The company operates a licensing-based business model, partnering with other biotech and CDMO firms to integrate CliCr® into their therapeutic and diagnostic development programs, positioning itself as an enabler rather than a direct drug developer.

CliCr®: a proprietary copper-free click chemistry reagent platform for bioconjugation, offering higher stability, faster reactions, and optimal conjugate yields for drug delivery and diagnostic applications.

Cristal competes in the life science tools and enabling technologies space, facing competition from other providers of click chemistry reagents (including copper-catalyzed alternatives) and bioconjugation technologies. Its key differentiation is the claimed performance benefits (speed, stability, yield) of its proprietary copper-free chemistry within the niche of high-value therapeutic conjugation.